Corcept Therapeutics reported that relacorilant, an oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a phase 3 trial for platinum‑resistant ovarian cancer and met a co‑primary overall survival endpoint. The firm said the result bolsters its pending FDA submission, with a PDUFA date set for July 11, 2026. Corcept’s announcement follows a prior complete response letter in a Cushing syndrome program; the company emphasized the ovarian cancer data as pivotal for oncology positioning. Analysts projected meaningful peak sales potential and noted the survival signal strengthens the drug’s approval prospects in a difficult-to-treat population.